يعرض 1 - 20 نتائج من 133 نتيجة بحث عن '"Ferrisse, Tulio Morandin"', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Academic Journal

    المساهمون: Fundação de Amparo à Pesquisa do Estado de São Paulo

    المصدر: Oral Diseases ; volume 30, issue 7, page 4740-4750 ; ISSN 1354-523X 1601-0825

  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal

    وصف الملف: application/pdf

    Relation: Fernandes, Darcy; Barbeiro, Camila de Oliveira; Palaçon, Mariana Paravani; Biancardi, Mariel Ruivo; Ferrisse, Túlio Morandin; Silveira, Heitor Albergoni; Castilho, Rogerio Moraes; Almeida, Luciana Yamamoto; Leon, Jorge Esquiche; Bufalino, Andreia (2023). "High density of CD8 T cell and immune imbalance of T lymphocytes subsets are associated with proliferative verrucous leukoplakia." Immunology 168(1): 96-109.; https://hdl.handle.net/2027.42/175525; Immunology; McDermott DF, Regan MM, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer. 2006; 5 ( 2 ): 114 – 9.; Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15: 486 – 99.; Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018; 69: 301 – 18.; Iwahori K. Cytotoxic CD8 + lymphocytes in the tumor microenvironment. Adv Exp Med Biol. 2020; 1224: 53 – 62.; Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007; 25: 171 – 92.; Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993; 362: 758 – 61.; Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998; 188: 2205 – 13.; Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8 + and CD163 + infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS. 2018; 126: 732 – 8.; Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13: 2151 – 7.; Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141: 39 – 51.; Maj T, Wei S, Welling T, Zou W. T cells and costimulation in cancer. Cancer J. 2013; 19 ( 6 ): 473 – 82.; Kuribayashi Y, Tsushima F, Morita KI, Matsumoto K, Sakurai J, Uesugi A, et al. Long-term outcome of non-surgical treatment in patients with oral leukoplakia. Oral Oncol. 2015; 51: 1020 – 5.; Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014; 27: 16 – 25.; Murakami N, Riella LV. Co-inhibitory pathways and their importance in immune regulation. Transplantation. 2014; 98: 3 – 14.; Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015; 36 ( 4 ): 265 – 76.; Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. 2019; 50 ( 4 ): 796 – 811.; Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009; 183 ( 7 ): 4169 – 75.; Gaur P, Singh AK, Shukla NK, Das SN. Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol. 2014; 75 ( 4 ): 330 – 7.; Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010; 107: 57 – 117.; Duan MC, Zhong XN, Liu GN, Wei JR. The Treg/Th17 paradigm in lung cancer. J Immunol Res. 2014; 2014: 730380.; Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH, et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol. 2010; 161 ( 3 ): 480 – 9.; Kesselring R, Thiel A, Pries R, Wollenberg B. The number of CD161 positive Th17 cells are decreased in head and neck cancer patients. Cell Immunol. 2011; 269 ( 2 ): 74 – 7.; Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4 + CD25 high Foxp3 + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13 ( 21 ): 6301 – 11.; Drennan S, Stafford ND, Greenman J, Green VL. Increased frequency and suppressive activity of CD127(low/−) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology. 2013; 140 ( 3 ): 335 – 43.; Sun W, Li WJ, Wu CY, Zhong H, Wen WP. CD45RA − Foxp3 high but not CD45RA + Foxp3 low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res. 2014; 33: 35.; Green VL, Michno A, Stafford ND, Greenman J. Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunol Immunother. 2013; 62 ( 5 ): 863 – 73.; Zhao Q, Wang PP, Huang ZL, Peng L, Lin C, Gao Z, et al. Tumoral indoleamine 2,3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma. Oncotarget. 2016; 7 ( 12 ): 14781 – 90.; Dutta A, Banerjee A, Saikia N, Phookan J, Baruah MN, Baruah S. Negative regulation of natural killer cell in tumor tissue and peripheral blood of oral squamous cell carcinoma. Cytokine. 2015; 76 ( 2 ): 123 – 30.; Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8 + T cell exhaustion during chronic viral infection. Immunity. 2007; 27: 670 – 84.; Basso FG, Pansani TN, Soares DG, Hebling J, de Souza Costa CA. LLLT effects on oral keratinocytes in an organotypic 3D model. Photochem Photobiol. 2018; 94 ( 1 ): 190 – 4.; El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. Tumours of the oral cavity and mobile tongue. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. World Health Organization (WHO) classification of head and neck tumours. International Agency for Research on Cancer (IARC). 4th ed. Lyon: IARC Press; 2017. p. 105 – 15.; Woo S-B. Oral epithelial dysplasia and premalignancy. Head Neck Pathol. 2019; 13 ( 3 ): 423 – 39.; Ranganathan K, Kavitha L. Oral epithelial dysplasia: classifications and clinical relevance in risk assessment of oral potentially malignant disorders. J Oral Maxillofac Pathol. 2019; 23 ( 1 ): 19 – 27.; Tilakaratne WM, Jayasooriya PR, Jayasuriya NS, De Silva RK. Oral epithelial dysplasia: causes, quantification, prognosis, and management challenges. Periodontol 2000. 2019; 80 ( 1 ): 126 – 47.; Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol. 2003; 39 ( 8 ): 770 – 80.; Villa A, Sonis S. Oral leukoplakia remains a challenging condition. Oral Dis. 2018; 24 ( 1–2 ): 179 – 83.; Bagan J, Scully C, Jimenez Y, Martorell M. Proliferative verrucous leukoplakia: a concise update. Oral Dis. 2010; 16 ( 4 ): 328 – 32.; Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2016; 45: 155 – 66.; Aguirre-Urizar JM, Lafuente-Ibáñez de Mendoza I, Warnakulasuriya S. Malignant transformation of oral leukoplakia: systematic review and meta-analysis of the last 5 years. Oral Dis. 2021; 27 ( 8 ): 1881 – 95.; Bagan JV, Jimenez Y, Sanchis JM, Poveda R, Milian MA, Murillo J, et al. Proliferative verrucous leukoplakia: high incidence of gingival squamous cell carcinoma. J Oral Pathol Med. 2003; 32 ( 7 ): 379 – 82.; Villa A, Woo SB. Leukoplakia – a diagnostic and management algorithm. J Oral Maxillofac Surg. 2017; 75 ( 4 ): 723 – 34.; Torrejon-Moya A, Jané-Salas E, López-López J. Clinical manifestations of oral proliferative verrucous leukoplakia: a systematic review. J Oral Pathol Med. 2020; 49 ( 5 ): 404 – 8.; Ramos-García P, González-Moles MÁ, Mello FW, Bagan JV, Warnakulasuriya S. Malignant transformation of oral proliferative verrucous leukoplakia: a systematic review and meta-analysis. Oral Dis. 2021; 27 ( 8 ): 1896 – 907.; Lafuente Ibáñez de Mendoza I, Lorenzo Pouso AI, Aguirre Urízar JM, Barba Montero C, Blanco Carrión A, Gándara Vila P, et al. Malignant development of proliferative verrucous/multifocal leukoplakia: a critical systematic review, meta-analysis and proposal of diagnostic criteria. J Oral Pathol Med. 2022; 51 ( 1 ): 30 – 8. https://doi.org/10.1111/jop.13246; Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6: 715 – 27.; Ai R, Tao Y, Hao Y, Jiang L, Dan H, Ji N, et al. Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. Oncotarget. 2017; 8 ( 46 ): 81617 – 35. https://doi.org/10.18632/oncotarget.20312; Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22: 329 – 60.; Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21 ( 2 ): 137 – 48.; Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90: 1 – 50.; Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646 – 74.; Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29: 235 – 71.; Brouns E, Baart J, Karagozoglu K, Aartman I, Bloemena E, van der Waal I. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis. 2014; 20: e19 – 24.; Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006; 42: 987 – 93.; Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epitelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008; 37 ( 3 ): 127 – 33.; Peske JD, Woods AB, Engelhard VH. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res. 2015; 128: 263 – 307.; Yagyuu T, Hatakeyama K, Imada M, Kurihara M, Matsusue Y, Yamamoto K, et al. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: implications for patients with oral precancerous lesions. Oral Oncol. 2017; 68: 36 – 43.

  13. 13
    Academic Journal
  14. 14
  15. 15
    Academic Journal
  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Conference

    المساهمون: Universidade Estadual Paulista (UNESP)

    وصف الملف: 150-156

    Relation: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology; 0,720; http://dx.doi.org/10.1016/j.oooo.2016.02.005; Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, v. 123, n. 2, p. 150-156, 2017.; http://hdl.handle.net/11449/172772; 2-s2.0-84962440618; 2-s2.0-84962440618.pdf

  19. 19
    Academic Journal
  20. 20
    Academic Journal

    المساهمون: Universidade Estadual Paulista (UNESP)

    Relation: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology; 0,153; http://dx.doi.org/10.1016/j.ajoms.2018.06.004; Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.; http://hdl.handle.net/11449/171165; 2-s2.0-85049350160; 2-s2.0-85049350160.pdf